Targeted radioactive therapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted radioactive drug that seeks out a specific marker on lung cancer cells. It first uses a low-dose imaging scan to see if the cancer cells have this marker, then gives a higher-dose treatment to destroy those cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have non-small cell lung cancer that has spread to other parts of the body and has continued to grow after at least one prior treatment.
- A stored sample of your tumor (from a biopsy) is available for testing.
- Your blood counts and liver/kidney function must be within certain safe ranges.
- You must be able to lie still for up to an hour for a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging scan and a targeted radiation treatment for certain cancers that have spread. First, a special PET scan finds tumors that light up; then, if eligible, you may receive a treatment that targets those same tumors.
This early study tests a two-step approach: a special PET/CT scan to find pancreatic cancer, followed by a targeted radiation medicine to attack it. It may help researchers learn whether this targeted approach is safe and able to reach pancreatic tumors after standard treatment.
This trial tests a new drug called 177Lu-DTPA-SC16.56, which delivers radiation directly to cancer cells that have a specific marker called DLL3. It is for people with high-grade neuroendocrine lung or prostate cancer that has spread and gotten worse after at least one round of chemotherapy.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Hear when a new Metastatic Nonsmall Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.